# OnCo record b-dose-optimisation (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-dose-optimisation/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-dose-optimisation" ;
  schema:name "Wrong doses"@en ;
  schema:description "Most drug doses were chosen as the highest a person can tolerate, which is often more than they need."@en ;
  schema:url <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus>, <https://doi.org/10.1056/NEJMp2109826>, <https://doi.org/10.1016/S0140-6736(19)30650-6> ;
  onco:related <https://onco.cc/collections/fda-approvals/>, <https://onco.cc/ideas/idea-shortened-venetoclax/>, <https://onco.cc/ideas/idea-desmoid-intermittent-dosing/>, <https://onco.cc/ideas/idea-net-dosimetry-prrt/>, <https://onco.cc/ideas/idea-total-body-pet-dosimetry/>, <https://onco.cc/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/>, <https://onco.cc/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/>, <https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/>, <https://onco.cc/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/>, <https://onco.cc/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/>, <https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/>, <https://onco.cc/ideas/idea-tr1-start-low-titrate-up-oral-agents/>, <https://onco.cc/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/>, <https://onco.cc/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/>, <https://onco.cc/ideas/idea-tr1-adc-dose-and-schedule-optimisation/>, <https://onco.cc/ideas/idea-tr1-dose-evidence-statement-in-label/>, <https://onco.cc/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/>, <https://onco.cc/ideas/idea-tr1-food-effect-dose-reduction/>, <https://onco.cc/ideas/idea-tr1-factorial-dose-finding-for-combinations/>, <https://onco.cc/ideas/idea-tr1-organ-impairment-pk-before-approval/>, <https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/>, <https://onco.cc/ideas/idea-tr1-response-adapted-dose-reduction/>, <https://onco.cc/ideas/idea-moon-individualised-dosing-all-oral-drugs/>, <https://onco.cc/ideas/idea-cost-low-dose-abiraterone-food/>, <https://onco.cc/ideas/idea-cost-low-dose-immunotherapy-trials/>, <https://onco.cc/ideas/idea-cost-optimus-legacy-drugs/>, <https://onco.cc/ideas/idea-cost-extended-interval-default/>, <https://onco.cc/ideas/idea-cost-shorter-course-trials/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/nirogacestat/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/finaldose/>, <https://onco.cc/companies/amgen/> ;
  onco:terms <https://onco.cc/terms/dosimetry/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/alpha-vs-beta/> ;
  onco:trials <https://onco.cc/trials/monarch-3/>, <https://onco.cc/trials/persephone/>, <https://onco.cc/trials/apt-trial/> .